Reports FY22 group sales CHF63.28B vs. CHF62.8B last year. Roche CEO Severin Schwan: "We achieved good results in 2022, even though the demand for COVID-19 products declined, as expected. The diagnostics base business and our newer medicines continued their strong growth. While we had pipeline setbacks in 2022, I am particularly pleased that we brought two new medicines to patients: Vabysmo for certain severe eye diseases and Lunsumio for a currently incurable form of blood cancer. For the current year we expect solid underlying growth in both divisions, which will largely compensate for the further significant drop in sales of roughly CHF 5 billion in COVID-19 products."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
- [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
- Roche reports EC approves label expansion of Hemlibra
- European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
- Roche price target lowered to CHF 350 from CHF 380 at Berenberg